{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T16:59:26Z","timestamp":1770483566450,"version":"3.49.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,4,15]]},"DOI":"10.2146\/ajhp110227","type":"journal-article","created":{"date-parts":[[2012,4,2]],"date-time":"2012-04-02T14:18:27Z","timestamp":1333376307000},"page":"651-657","source":"Crossref","is-referenced-by-count":15,"title":["Ecallantide for treatment of acute attacks of hereditary angioedema"],"prefix":"10.1093","volume":"69","author":[{"given":"Jay L.","family":"Martello","sequence":"first","affiliation":[{"name":"School of Pharmacy, West Virginia University, Morgantown"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie R.","family":"Woytowish","sequence":"additional","affiliation":[{"name":"West Virginia University Hospitals and School of Pharmacy, Morgantown"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Chambers","sequence":"additional","affiliation":[{"name":"West Virginia University Hospitals and School of Pharmacy, Morgantown"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"2019041203510449100_b1-0690651","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1146\/annurev.iy.06.040188.003115","article-title":"C1 inhibitor and hereditary angioneurotic edema","volume":"6","author":"Davis","year":"1988","journal-title":"Annu Rev Immunol."},{"key":"2019041203510449100_b2-0690651","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1056\/NEJMcp0803977","article-title":"Hereditary angioedema","volume":"359","author":"Zuraw","year":"2008","journal-title":"N Engl J Med."},{"key":"2019041203510449100_b3-0690651","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.amjmed.2007.09.024","article-title":"The spectrum and treatment of angioedema","volume":"121","author":"Temino","year":"2008","journal-title":"Am J Med."},{"key":"2019041203510449100_b4-0690651","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1365-2249.2005.02726.x","article-title":"C1 inhibitor deficiency: consensus document","volume":"139","author":"Gompels","year":"2005","journal-title":"Clin Exp Immunol."},{"key":"2019041203510449100_b5-0690651","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1710-1492-6-24","article-title":"2010 International consensus algorithm for the diagnosis, therapy, and management of hereditary angioedema","volume":"6","author":"Bowen","year":"2010","journal-title":"Allergy Asthma Clin Immunol."},{"key":"2019041203510449100_b6-0690651","unstructured":"Drugs@FDA. FDA approved drug products search (Berinert). www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/ (accessed 2010 Dec 12)."},{"key":"2019041203510449100_b7-0690651","unstructured":"Shire. FDA approves Shire\u2019s Firazyr (icatibant injection) for acute attacks of hereditary angioedema (HAE). www.shire.com\/shireplc\/en\/investors\/irshirenews?id=520 (accessed 2012 Jan 6)."},{"key":"2019041203510449100_b8-0690651","unstructured":"Drugs@FDA. FDA approved drug products search (Kalbitor). www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/ (accessed 2010 Dec 12)."},{"key":"2019041203510449100_b9-0690651","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1517\/13543784.17.5.697","article-title":"New promise and hope for treating hereditary angioedema","volume":"17","author":"Zuraw","year":"2008","journal-title":"Expert Opin Investig Drugs."},{"key":"2019041203510449100_b10-0690651","volume-title":"Kalbitor (ecallantide) prescribing information","year":"2009"},{"key":"2019041203510449100_b11-0690651","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2165\/11205850-000000000-00000","article-title":"Ecallantide in acute hereditary angioedema","volume":"70","author":"Garnock-Jones","year":"2010","journal-title":"Drugs."},{"key":"2019041203510449100_b12-0690651","unstructured":"European Medicines Agency. Firazyr prescribing information. www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Informa-tion\/human\/000899\/WC500022966.pdf (accessed 2011 Jul 1)."},{"key":"2019041203510449100_b13-0690651","first-page":"197","article-title":"DX-88 a recombinant inhibitor of human plasma kallikrein. Efficacy and safety in hereditary and acquired angioedema","volume":"40","author":"Cicardi","year":"2003","journal-title":"Mol Immunol."},{"key":"2019041203510449100_b14-0690651","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.jaci.2007.04.028","article-title":"Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor","volume":"120","author":"Schneider","year":"2007","journal-title":"J Allergy Clin Immunol."},{"key":"2019041203510449100_b15-0690651","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.1016\/j.jaci.2005.12.715","article-title":"Interim results of EDEMA2, a multicentre, open-label, repeat-dosing study of intravenous and subcutaneous administration of ecallantide (DX-88) in hereditary angioedema","volume":"117","author":"Lumry","year":"2006","journal-title":"J Allergy Clin Immunol."},{"key":"2019041203510449100_b16-0690651","unstructured":"Positive final results from EDEMA2 trial with DX-88 for the treatment of hereditary angioedema presented at ACAAI meeting. www.businesswire.com\/news\/home\/20061114005249\/en\/Positive-Final-Results-EDEMA2-Trial-DX-88-Treatment (accessed 2010 Dec 28)."},{"key":"2019041203510449100_b17-0690651","unstructured":"Limb\n              S\n            \n          . FDA Pulmonary-Allergy Drugs Advisory Committee briefing document: Kalbitor (ecallantide) 30 mg for the treatment of acute attacks of hereditary angioedema. www.fda.gov\/ohrms\/dockets\/ac\/09\/briefing\/2009-4413b1-00-FDA-index.htm (accessed 2010 Dec 28)."},{"key":"2019041203510449100_b18-0690651","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa0905079","article-title":"Ecallantide for the treatment of acute attacks of hereditary angioedema","volume":"363","author":"Cicardi","year":"2010","journal-title":"N Engl J Med."},{"key":"2019041203510449100_b19-0690651","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s11136-009-9509-8","article-title":"Psychometric validation of two patient-reported outcome measures to assess symptom severity and changes and changes in symptoms in hereditary angioedema","volume":"18","author":"Vernon","year":"2009","journal-title":"Qual Life Res."},{"key":"2019041203510449100_b20-0690651","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.anai.2010.04.012","article-title":"EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema","volume":"104","author":"Levy","year":"2010","journal-title":"Ann Allergy Asthma Immunol."},{"key":"2019041203510449100_b21-0690651","unstructured":"Clinicaltrials.gov. Studies search (Kalbitor). http:\/\/clinicaltrials.gov\/ct2\/results?term=ecallantide (accessed 2010 Dec 18)."},{"key":"2019041203510449100_b22-0690651","unstructured":"Kalbitor important safety information for healthcare professionals, risk evaluation and mitigation strategy (REMS). www.kalbitor.com\/hcp\/rems.html (accessed 2011 Jul 1)."},{"key":"2019041203510449100_b23-0690651","unstructured":"Medi-Span drug price analysis from PriceRx. Drug search (Kalbitor). www.medispan.com\/drug-pricing-analysis-pricerx.aspx (accessed 2011 Apr 12)."},{"key":"2019041203510449100_b24-0690651","volume-title":"Berinert (C1 esterase inhibitor, human) prescribing information","year":"2009"},{"key":"2019041203510449100_b25-0690651","unstructured":"Kalbitor Access Program. www.kalbitor.com\/patient\/access-program.html (accessed 2011 Apr 12)."},{"key":"2019041203510449100_b26-0690651","unstructured":"Shire. OnePath homepage. www.onepath.com (accessed 2012 Jan 6)."},{"key":"2019041203510449100_b27-0690651","volume-title":"Firazyr (icatibant) prescribing information","year":"2011"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/69\/8\/651\/28361043\/ajhp0651.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T19:42:06Z","timestamp":1555098126000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/69\/8\/651\/5112208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,15]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,4,15]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp110227","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2012,4,15]]},"published":{"date-parts":[[2012,4,15]]}}}